🇺🇸 FDA
Pipeline program

Methylphenidate + SPD503 (Guanfacine hydrochloride)

SPD503-205

Phase 2 small_molecule completed

Quick answer

Methylphenidate + SPD503 (Guanfacine hydrochloride) for Attention Deficit Disorder With Hyperactivity is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Attention Deficit Disorder With Hyperactivity
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials